CS Diagnostics Corp. (CSDX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CS Diagnostics Corp. (CSDX) trades at $0.06 with AI Score 57/100 (Grade B). CS Diagnostics Corp. focuses on developing and distributing wellness and medical products, including disinfectants and tissue spacers. Market cap: $15.00M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for CSDX: CSDX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CSDX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CSDX: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →CS Diagnostics Corp. (CSDX) Healthcare & Pipeline Overview
CS Diagnostics Corp., based in Germany, develops and sells wellness and medical devices, including the MEDUSA disinfectant and CS-Protect Hydrogel tissue spacer. With a high P/E ratio of 758.42 and a market cap of $15.00M, the company operates in the competitive medical device sector, balancing innovation with market penetration.
What Is the Investment Thesis for CSDX?
CS Diagnostics Corp. presents a high-risk, high-reward investment profile. The company's small market capitalization of $15.00M and high P/E ratio of 758.42 indicate a potentially overvalued stock or expectations of significant future growth. A key value driver is the potential market adoption of its MEDUSA disinfectant and CS-Protect Hydrogel, particularly if clinical studies support their efficacy. Growth catalysts include expanding distribution networks internationally and securing regulatory approvals in new markets. However, the negative beta of -23.92 suggests extreme volatility and sensitivity to market fluctuations. Investors should carefully weigh the potential for rapid growth against the risks associated with a small-cap company operating in a competitive sector.
Based on FMP financials and quantitative analysis
CSDX Key Highlights
- Market Cap of $15.00M indicates a small-cap company with potential for high growth but also higher risk.
- P/E Ratio of 758.42 suggests the stock may be overvalued or that investors anticipate significant earnings growth.
- Profit Margin of 31.9% demonstrates the company's ability to generate profit from its sales.
- Gross Margin of 30.4% reflects the efficiency of the company's production and pricing strategies.
- Beta of -23.92 indicates the stock is highly volatile and moves inversely to the market.
Who Are CSDX's Competitors?
CSDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMRR American Metals Recovery and Recycling Inc. | $1.30 | +0.00% | $250.61M | 44 |
| CINV Crucial Innovations Corp. | $4.55 | +0.00% | $338.60M | 44 |
| DVTC Development Technologies Corp. | $5.00 | +0.00% | $272.50M | 44 |
| FRFZF Fairfax Financial Holdings Limited | $16.01 | -1.75% | $357.54M | 44 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CSDX's Key Strengths?
- Proprietary product formulations (MEDUSA and CS-Protect Hydrogel).
- Specialized expertise in niche medical applications.
- Established presence in the German market.
- High profit margin of 31.9%.
What Are CSDX's Weaknesses?
- Small market capitalization limits access to capital.
- High P/E ratio suggests potential overvaluation.
- Limited international presence.
- Dependence on a small number of key products.
What Could Drive CSDX Stock Higher?
- Potential regulatory approvals for MEDUSA in new markets could drive revenue growth.
- Expansion of the distribution network in Europe could increase market reach.
- Clinical studies validating the efficacy of CS-Protect Hydrogel could boost adoption.
- Development of new product lines targeting unmet needs in healthcare.
- Strategic partnerships with hospitals and clinics could provide access to new customers.
What Are the Key Risks for CSDX?
- Intense competition from larger medical device companies could limit market share.
- Stringent regulatory requirements and potential delays could impact product launches.
- Product liability risks associated with medical devices.
- Small market capitalization limits access to capital.
- High P/E ratio suggests potential overvaluation.
What Are the Growth Opportunities for CSDX?
- Expanding International Distribution: CS Diagnostics has the opportunity to expand its distribution network beyond Germany into other European markets and potentially North America. The global disinfectant market is projected to reach billions of dollars, offering a substantial market for MEDUSA. Success hinges on securing regulatory approvals and establishing partnerships with local distributors. Timeline: 2-3 years.
- Securing Regulatory Approvals: Obtaining regulatory approvals, such as CE marking for new applications or FDA clearance in the United States, can significantly expand the market reach for CS-Protect Hydrogel and MEDUSA. The market for tissue spacers in radiation therapy is growing, driven by advancements in cancer treatment. Timeline: 1-2 years per approval.
- Developing New Product Lines: CS Diagnostics can leverage its expertise in medical devices to develop new product lines targeting unmet needs in healthcare. This could include advanced wound care products or innovative diagnostic tools. The medical device market is constantly evolving, creating opportunities for companies that can innovate and adapt. Timeline: 3-5 years.
- Strategic Partnerships: Forming strategic partnerships with hospitals, clinics, and other healthcare providers can provide CS Diagnostics with access to new markets and customers. These partnerships can also facilitate clinical trials and product validation. The healthcare industry relies on collaboration to drive innovation and improve patient outcomes. Timeline: Ongoing.
- Capitalizing on Telehealth Trends: Integrating its products with telehealth platforms could provide CS Diagnostics with a competitive advantage. Remote monitoring and treatment are becoming increasingly common, creating opportunities for devices that can be used in home healthcare settings. The telehealth market is experiencing rapid growth, driven by technological advancements and changing patient preferences. Timeline: 2-3 years.
What Opportunities Does CSDX Have?
- Expanding distribution into new geographic markets.
- Securing regulatory approvals for existing products.
- Developing new product lines to address unmet needs.
- Forming strategic partnerships with healthcare providers.
What Threats Does CSDX Face?
- Intense competition from larger medical device companies.
- Stringent regulatory requirements and potential delays.
- Product liability risks associated with medical devices.
- Economic downturns impacting healthcare spending.
What Are CSDX's Competitive Advantages?
- Proprietary product formulations (MEDUSA and CS-Protect Hydrogel).
- Specialized expertise in disinfection and radiation therapy support.
- Established distribution network in Germany.
- Potential for strong relationships with key healthcare providers.
What Does CSDX Do?
CS Diagnostics Corp., formerly known as FlashZero Corp., was founded in 1996 and is headquartered in Neuss, Germany. The company rebranded in August 2023 to reflect its focus on the healthcare sector. CS Diagnostics specializes in the design, manufacture, and distribution of wellness and medical products. Its flagship product, MEDUSA, is a proprietary surface disinfectant aimed at reducing infection risks in healthcare settings. Another key product is CS-Protect Hydrogel, a tissue spacer used in radiation therapy to minimize damage to healthy tissue during cancer treatment. CS Diagnostics operates both within Germany and internationally, seeking to expand its market reach through strategic partnerships and direct sales. The company's product portfolio targets specific needs within the medical field, emphasizing innovative solutions for infection control and radiation oncology. Despite its small market capitalization, CS Diagnostics maintains a presence in a competitive landscape, striving to differentiate itself through product efficacy and specialized applications.
What Products and Services Does CSDX Offer?
- Designs and manufactures wellness and medical products.
- Offers MEDUSA, a proprietary surface disinfectant product.
- Provides CS-Protect Hydrogel, a tissue spacer gel for radiation therapy.
- Distributes products in Germany and internationally.
- Focuses on innovative solutions for infection control.
- Aims to improve patient outcomes through specialized medical devices.
How Does CSDX Make Money?
- Develops and manufactures specialized medical products.
- Sells products directly to hospitals, clinics, and healthcare providers.
- Distributes products through partnerships in international markets.
- Generates revenue through product sales and licensing agreements.
What Industry Does CSDX Operate In?
CS Diagnostics Corp. operates within the medical device industry, a sector characterized by constant innovation and stringent regulatory requirements. The global medical device market is projected to reach hundreds of billions of dollars by 2026, driven by an aging population and increasing healthcare spending. Competition is intense, with established players like AMRR and smaller, specialized firms vying for market share. CS Diagnostics focuses on niche areas such as disinfection and radiation therapy support, aiming to differentiate itself through specialized products. Success in this industry requires continuous R&D, regulatory compliance, and effective marketing strategies.
Who Are CSDX's Key Customers?
- Hospitals and clinics seeking effective disinfection solutions.
- Radiation oncology centers using tissue spacers.
- Healthcare providers focused on patient safety.
- International distributors of medical devices.
Company Profile
CS Diagnostics Corp. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Neuss, DE. The company is led by CEO Thomas Fahrhoefer. CSDX has traded publicly since 2005.
CS Diagnostics Corp. Financial Trajectory
CS Diagnostics Corp. (CSDX) reported $23K in revenue for Q3 2025, reflecting 3057.5% growth compared to the prior quarter. The company recorded a net loss of $182, with diluted EPS of $0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.
How CS Diagnostics Corp. Is Valued
CS Diagnostics Corp. carries a market capitalization of $15.00M, placing it in the micro-cap category. Relative to its peer group, CSDX's quantitative score of 57/100 is roughly in line with the peer average of 50/100.
ROE 0%Key Financial Metrics
Return on equity for CS Diagnostics Corp. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. CSDX trades at a trailing price-to-earnings ratio of 115.84, above the Healthcare sector average of ~23x. Its free cash flow yield is 0.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.61 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
CS Diagnostics Corp.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
CSDX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- CSDX insiders buying shares lately – usually a good sign they think the company is undervalued.
- The buzz in the trading community is that CSDX's new diagnostic tool could be a game-changer.
- Lately, I've seen a lot of talk about partnerships and expansions, which could mean bigger market share for CSDX.
- Remember Tesla in 2020? Sometimes market sentiment can drive a stock way beyond fundamentals – CSDX could be riding that wave.
Bear Case
- I'm seeing chatter about potential regulatory hurdles for their new product, which could slow things down.
- The overall market is jittery right now; even good news might not be enough to keep CSDX afloat.
- Lots of debate about whether CSDX can really scale up production to meet demand if their product takes off.
- Feels like some of the bullish sentiment might be based on hype rather than concrete progress – reminds me a bit of the dot-com bubble.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $23,050 | -$182 | $0.00 |
| Q2 2025 | $730 | $196 | $0.00 |
| Q1 2025 | $70,420 | $32,067 | $0.0002 |
Based on FMP financials and quantitative analysis
CSDX Latest News
No recent news available for CSDX.
CSDX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CSDX.
Price Targets
Wall Street price target analysis for CSDX.
CSDX MoonshotScore
What does this score mean?
The MoonshotScore rates CSDX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Thomas Fahrhoefer
CEO
Thomas Fahrhoefer serves as the CEO of CS Diagnostics Corp. His background includes extensive experience in the healthcare industry, with a focus on medical device development and commercialization. Prior to joining CS Diagnostics, Fahrhoefer held leadership positions at several medical technology companies, where he oversaw product development, regulatory affairs, and marketing strategies. He holds an advanced degree in biomedical engineering and has published numerous articles on medical device innovation.
Track Record: Under Thomas Fahrhoefer's leadership, CS Diagnostics Corp. has focused on expanding its product portfolio and strengthening its market position. Key achievements include the successful launch of CS-Protect Hydrogel and the expansion of the MEDUSA disinfectant line. Fahrhoefer has also overseen efforts to secure regulatory approvals in new markets and establish strategic partnerships with healthcare providers. His strategic decisions have contributed to the company's growth and profitability.
CSDX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CS Diagnostics Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies are not required to be SEC reporting companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in CSDX.
- Low trading volume and liquidity can lead to price volatility.
- Potential for fraud or manipulation due to lack of regulatory oversight.
- Higher risk of delisting or going out of business.
- OTC Other stocks are not required to be SEC reporting companies.
- Verify the company's management team and their track record.
- Review any available financial statements and assess the company's financial health.
- Research the company's products and services and their market potential.
- Check for any legal or regulatory issues.
- Assess the liquidity of the stock and the potential for price volatility.
- Understand the risks associated with investing in OTC Other stocks.
- Confirm the company's registration and compliance status.
- The company has been in operation since 1996.
- CS Diagnostics Corp. has a functional website and contact information.
- The company has a CEO, Thomas Fahrhoefer, with relevant industry experience.
- The company develops and sells tangible products (disinfectant and hydrogel).
- The company has a profit margin of 31.9%.
CSDX Healthcare Stock FAQ
What does CS Diagnostics Corp. do?
CS Diagnostics Corp. is a German-based company that develops, manufactures, and sells wellness and medical products. Its primary offerings include MEDUSA, a proprietary surface disinfectant, and CS-Protect Hydrogel, a tissue spacer used in radiation therapy. The company targets hospitals, clinics, and other healthcare providers, providing solutions for infection control and radiation oncology. CS Diagnostics operates both in Germany and internationally, aiming to expand its market reach through strategic partnerships and direct sales. The company focuses on niche areas within the medical device industry, emphasizing innovative solutions for specific healthcare needs.
What are the main risks for CSDX?
CS Diagnostics Corp. faces several risks, including intense competition from larger medical device companies, stringent regulatory requirements, and potential product liability issues. The company's small market capitalization limits its access to capital, which could hinder its ability to fund research and development or expand its operations. The high P/E ratio suggests potential overvaluation, making the stock vulnerable to market corrections. Additionally, the company operates on the OTC Other tier, which carries increased risks due to limited financial disclosure and regulatory oversight. Investors should carefully consider these risks before investing in CSDX.
What are the key factors to evaluate for CSDX?
CS Diagnostics Corp. (CSDX) holds an AI score of 57/100 (moderate). Not financial advice.
How frequently does CSDX data refresh on this page?
CSDX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CSDX's recent stock price performance?
CS Diagnostics Corp. (CSDX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary product formulations (MEDUSA and CS-Protect Hydrogel). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CSDX overvalued or undervalued right now?
Valuing CS Diagnostics Corp. (CSDX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CSDX?
Before investing in CS Diagnostics Corp. (CSDX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CSDX to a portfolio?
Key strength of CS Diagnostics Corp. (CSDX): Proprietary product formulations (MEDUSA and CS-Protect Hydrogel). Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be limited or delayed.
- AI analysis pending for CSDX.